Functional characterisation of the major susceptibility locus (PSORS1) for cutaneous inflammation in psoriasis

Psoriasis patients carry a specific genetic region, PSORS1, that dramatically raises their risk of developing the chronic skin condition, and this project will pinpoint exactly which genes in that region drive the inflammation. The problem is that current treatments manage symptoms but do not address the root cause. Researchers know that psoriasis involves a breakdown in the skin’s barrier function, a misfiring immune system, or both, but they do not understand the fundamental molecular defect that triggers the disease. Without that knowledge, developing preventive or curative therapies remains guesswork. If this work succeeds, it could identify the precise biological pathway that goes wrong in psoriasis. That would allow drug developers to target the cause rather than the symptoms, potentially leading to treatments that prevent flare-ups or even cure the condition. The economic and health burden of chronic inflammation—lifelong medication, doctor visits, lost productivity—could drop significantly. This is fundamental science: it characterises a genetic risk factor at the molecular level. Similar work on other autoimmune genes has led directly to new classes of drugs, such as biologics for rheumatoid arthritis.